Ontology highlight
ABSTRACT:
SUBMITTER: Chen L
PROVIDER: S-EPMC6205194 | biostudies-literature | 2018 Sep
REPOSITORIES: biostudies-literature
Chen Limo L Diao Lixia L Yang Yongbin Y Yi Xiaohui X Rodriguez B Leticia BL Li Yanli Y Villalobos Pamela A PA Cascone Tina T Liu Xi X Tan Lin L Lorenzi Philip L PL Huang Anfei A Zhao Qiang Q Peng Di D Fradette Jared J JJ Peng David H DH Ungewiss Christin C Roybal Jonathon J Tong Pan P Oba Junna J Skoulidis Ferdinandos F Peng Weiyi W Carter Brett W BW Gay Carl M CM Fan Youhong Y Class Caleb A CA Zhu Jingfen J Rodriguez-Canales Jaime J Kawakami Masanori M Byers Lauren Averett LA Woodman Scott E SE Papadimitrakopoulou Vassiliki A VA Dmitrovsky Ethan E Wang Jing J Ullrich Stephen E SE Wistuba Ignacio I II Heymach John V JV Qin F Xiao-Feng FX Gibbons Don L DL
Cancer discovery 20180716 9
Although treatment with immune checkpoint inhibitors provides promising benefit for patients with cancer, optimal use is encumbered by high resistance rates and requires a thorough understanding of resistance mechanisms. We observed that tumors treated with PD-1/PD-L1 blocking antibodies develop resistance through the upregulation of CD38, which is induced by all-trans retinoic acid and IFNβ in the tumor microenvironment. <i>In vitro</i> and <i>in vivo</i> studies demonstrate that CD38 inhibits ...[more]